Mind Medicine Stock Alpha and Beta Analysis
| MNMD Stock | USD 7.56 0.47 6.63% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Mind Medicine. It also helps investors analyze the systematic and unsystematic risks associated with investing in Mind Medicine over a specified time horizon. Remember, high Mind Medicine's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Mind Medicine's market risk premium analysis include:
Beta 3.11 | Alpha 0.0762 | Risk 4.75 | Sharpe Ratio 0.0868 | Expected Return 0.41 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Mind |
Mind Medicine Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Mind Medicine market risk premium is the additional return an investor will receive from holding Mind Medicine long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Mind Medicine. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Mind Medicine's performance over market.| α | 0.08 | β | 3.11 |
Mind Medicine expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Mind Medicine's Buy-and-hold return. Our buy-and-hold chart shows how Mind Medicine performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Mind Medicine Market Price Analysis
Market price analysis indicators help investors to evaluate how Mind Medicine stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Mind Medicine shares will generate the highest return on investment. By understating and applying Mind Medicine stock market price indicators, traders can identify Mind Medicine position entry and exit signals to maximize returns.
Mind Medicine Return and Market Media
The median price of Mind Medicine for the period between Tue, Aug 27, 2024 and Mon, Nov 25, 2024 is 6.12 with a coefficient of variation of 12.96. The daily time series for the period is distributed with a sample standard deviation of 0.82, arithmetic mean of 6.34, and mean deviation of 0.59. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Disposition of 32595 shares by Halperin Wernli Miri of Mind Medicine at 6.17 subject to Rule 16b-3 | 09/03/2024 |
2 | OurPsychedelic Compound-Based Clinical-Stage Drug Stocks Portfolio Was Down 16 percent In August | 09/06/2024 |
3 | Psychedelic Drug Stocks 6 percent Last Week Vs. -13 percent Previous Week | 09/16/2024 |
4 | Disposition of 4430 shares by Sullivan Mark of Mind Medicine at 5.98 subject to Rule 16b-3 | 09/25/2024 |
5 | MindMed executive sells over 26k in company stock | 09/26/2024 |
6 | Disposition of 1264 shares by Robert Barrow of Mind Medicine at 5.51 subject to Rule 16b-3 | 10/11/2024 |
7 | Mind Medicine Coverage Initiated at Leerink Partners | 10/14/2024 |
8 | MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2024 Financial Results and Provide Business Update | 10/24/2024 |
9 | Acquisition by Wernli Miri Halperin of 100000 shares of Mind Medicine subject to Rule 16b-3 | 11/04/2024 |
10 | Mind Medicine Inc Q3 2024 Earnings Call Highlights Strong Cash Position and Clinical ... | 11/08/2024 |
11 | AI And Psychedelics A Marriage Made In Heaven For Mental Health Care | 11/13/2024 |
12 | COMMODORE CAPITAL LP Acquires Shares in Mind Medicine Inc | 11/15/2024 |
13 | Q3 EPS Estimate for Mind Medicine Cut by Analyst - MarketBeat | 11/22/2024 |
About Mind Medicine Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Mind or other stocks. Alpha measures the amount that position in Mind Medicine has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 (projected) | PB Ratio | 1.83 | 1.82 | Capex To Depreciation | 53.93 | 51.24 |
Mind Medicine Upcoming Company Events
As portrayed in its financial statements, the presentation of Mind Medicine's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Mind Medicine's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Mind Medicine's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Mind Medicine. Please utilize our Beneish M Score to check the likelihood of Mind Medicine's management manipulating its earnings.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Mind Medicine
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Mind Medicine Backtesting, Mind Medicine Valuation, Mind Medicine Correlation, Mind Medicine Hype Analysis, Mind Medicine Volatility, Mind Medicine History and analyze Mind Medicine Performance. For information on how to trade Mind Stock refer to our How to Trade Mind Stock guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Mind Medicine technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.